CN102907606A - Beta-glucan composition and application thereof - Google Patents
Beta-glucan composition and application thereof Download PDFInfo
- Publication number
- CN102907606A CN102907606A CN2012104607885A CN201210460788A CN102907606A CN 102907606 A CN102907606 A CN 102907606A CN 2012104607885 A CN2012104607885 A CN 2012104607885A CN 201210460788 A CN201210460788 A CN 201210460788A CN 102907606 A CN102907606 A CN 102907606A
- Authority
- CN
- China
- Prior art keywords
- beta
- glucan
- test
- meal
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a beta-glucan composition, which consists of the following raw materials in percentage by weight: 7.5 to 100 percent of beta-glucan powder, 0 to 30 percent of superfine carrot powder, 0 to 30 percent of superfine highland barley, 0 to 20 percent of erythritol, and 0 to 20 percent of isomaltooligosacharide. The composition has the functions of reducing blood fat and cholesterol, and the selected materials are medicinal and edible plants or plant extract, so that the beta-glucan composition is safe and non-toxic, can be eaten for a long time without toxic or side effect.
Description
Technical field
The present invention relates to health food processing technique field, relate in particular to a kind of beta-glucan composition and application thereof.
Background technology
Diabetes have become the chronic disease of the 3rd large serious threat human health after tumour, cardio cerebrovascular affection.At present there is 1.2 hundred million diabetic in the whole world, Chinese patients number row the second in the world, more than 20 years old adult's onset diabetes rate up to 9.6%,, estimate to have reached 92,400,000 people.China also has a large amount of people who is in prediabetes (anti-sugar amount is unusual), accounts for 15.5%.The harm of diabetes also is various complication, and 1/2 IDDM patient and 2/3 patients with NIDDM have a kind of chronic complicating diseases of diabetes at least.Calendar year 2001 chronic complicating diseases investigation group of Chinese Medical Association's diabetology branch report in hospital type II diabetes complication illness rate is respectively: hypertension 34.2%, cranial vascular disease 12.6%, angiocardiopathy 17.1%, lower limb vascular disease 5.2%.The required medical expense of cardiovascular disease prevention is accounted for topmost part in the diabetes medical expense.The people such as Chen Xinbao were investigation in 2003, and the medical treatment cost for the treatment of type II diabetes has accounted for per capita 77.8% ~ 177.9%(different cities of annual income of required expense).
The product that has in the market hypoglycemic is many.Hypoglycemic medicine is divided into Western medicine and Chinese medicine, and the hypoglycemic Western medicine roughly is divided into orally-taken blood sugar reducing medicine and injection hypoglycemic medicine.Wherein domestic orally-taken blood sugar reducing medicine commonly used is divided into non-insulin class Drugs Promoting Insulin Secretion class, biguanides, alpha-glucosidase inhibitor class, insulin sensitizer take non-insulin class medicine as main at present.Wherein the Drugs Promoting Insulin Secretion class is divided into again sulfonylureas and non-sulfonylureas (meglitinide).The injection hypoglycemic medicine is mainly take insulin and similar medicine thereof as main.This class medicine long-term taking side effect is larger, and is large on the impact of liver kidney, often causes nausea, the symptom such as vomiting, apocleisis, anorexia.
Hypoglycemic pcm common by diabetes pill, diabetes pill, clonidine capsule etc., this class Chinese patent drug is to come according to China's traditional medicine prescription, also has the active component that extracts from Chinese medicine, natural drug to make.This class medicine need to come medication according to different symptoms and physique, and the symptom of nausea,vomiting,diarrhea etc. is also arranged in the time of medication.
Lipid lowerers commonly used is the special class of Statins, shellfish, nicotinic acid class, cholic acid chelating agent, cholesterol absorption inhibitor five large classes, but these medicine long-term taking side effects are larger, common gastrointestinal reaction, nauseating, diarrhoea or constipation, headache, and severe patient can cause hepatic lesion.
02113578.9 1 kinds of hypoglycemics of Chinese patent ZL fat-reducing beans are take konjaku powder and soluble dietary fiber as primary raw material, add evening primrose oil, perilla oil and vitamin E, adopt the product of the sugared beans shape that conventional method makes.This invention is to utilize polydextrose in the konjaku and soluble dietary fiber in the effect of hypoglycemic.
Chinese patent ZL02139449.0 Tianqi sugar-reducing capsule is that the Radix Astragali, root of Chinese trichosanthes, the fruit of glossy privet, the stem of noble dendrobium, sun-dried ginseng, the root bark of Chinese wolf-berry, the coptis, Fructus Corni, eclipta, these processing of crude drugs of Chinese gall form.These compositions are medicinal plant entirely, belong to the antidiabetic drug of Chinese medicine class, long-term taking, and side effect is larger.
Chinese patent 200810181494.2 fat-eliminating antihypelipidemic health teas are to select lotus leaf, root of Chinese trichosanthes, living hawthorn, reed rhizome, blue or green tea, lotus, rhizoma nelumbinis and gynostemma pentaphylla as raw material, form through Preparation process.This invention mainly is to select to disappear the plant of lipid, accelerates metabolism and the discharge of fat, utilizes selected plant to treat diabetes in the mode of the tonifying yin of promoting the production of body fluid.
A kind of soft capsule of making as raw material take avenabeta glucosan and linseed oil is provided in patent of invention 200910143155.X avenabeta glucosan capsule for descend of blood fat and preparation method thereof.This invention mainly has the effect that reduces T-CHOL removing triglycerides, simultaneously auxiliary hyperglycemic.
-glucan is a kind of functional polysaccharide that is rich in Cereals class crop and the microorganism wall.Modern medicine and nutrition studies show that it have regulate immunity of organism, anticancer, antitumor, reduce cholesterol, regulate the several functions such as blood fat and blood sugar.Beta glucan mainly is to extract from yeast, oat and barley at present.United states drug food control office and food security office of European Union meals, nutrition and irritated expert group are thought: every daily ingestion 3 gram beta glucans can be effectively hypoglycemic, reduce blood low-density lipoprotein and total blood cholesterol levels content, reduces the ill risk of cardiovascular and cerebrovascular disease.The extraction of cereal beta glucan both at home and abroad is mainly take oat as main, but Australia, the British Commonwealth is industrial confirms with the clinical testing of the mechanism such as Science Institute, the barley beta glucan than avenabeta glucosan reducing blood lipid, regulate aspect the blood sugar even more ideal.In January, 2006, FDA determines that oat and barley equate for the effect that reduces Blood Cholesterol.Therefore conclude, eat the whole grain barley that contains β-glucan or the barley product that some dry method grinds, can help to reduce the concentration of Blood Cholesterol.So FDA is revising federal regulations code (CFR) the 21st and compiling the 101.81st part, the barley product that whole grain barley and some dry method are ground is included as the material that meets the dangerous Health Claims condition of soluble dietary fiber-heart disease.
Summary of the invention
Technical problem to be solved by this invention provide a kind of can be effectively hypoglycemic, reduce the beta-glucan composition of cholesterol effect.
Another technical problem to be solved by this invention provides this beta-glucan composition and is being used for hypoglycemic, as to reduce food, health food and the medicine of cholesterol application.
For addressing the above problem, a kind of beta-glucan composition of the present invention is characterized in that: said composition is comprised of the raw material of following weight ratio: beta glucan powder 7.5 ~ 100%, ultra micro carrot meal 0 ~ 30%, ultra micro highland barley flour 0 ~ 30%, antierythrite 0 ~ 20%, isomalto-oligosaccharide 0 ~ 20%.
A kind of from the yeast, oat, barley or the highland barley that cross 60 ~ 120 mesh sieves of described beta glucan powder, and beta glucan mass content wherein 〉=20%.
A kind of from yeast, oat, barley or the highland barley of described beta glucan powder, and beta glucan mass content wherein 〉=35%.
One or more replacements in the balsam pear of described ultra micro carrot meal usefulness ultra micro, pumpkin, green tea, konjaku, hawthorn, ginkgo leaf, PORIA ALBA, lotus leaf, Chinese yam, the red date.
One or more replacements in described ultra micro highland barley flour corn, cocoa power, brown rice, the brewer's yeast.
The food that aforesaid a kind of beta-glucan composition is hypoglycemic in preparation, reduce cholesterol or the application in health food or the medicine is characterized in that: contain this beta-glucan composition according to a conventional method granulation electuary, tablet, chewable tablets or capsule.
The present invention compared with prior art has the following advantages:
1, beta glucan is a kind of nutritional labeling inhibitor in nutrition among the present invention, and contain multivitamin and trace element in the carrot of selection collocation and the highland barley, so that at edible beta glucan while microelement-supplementing and vitamin, remedied separately edible beta glucan to the inhibition of Nutrient Absorption, simultaneously improve diabetic or prediabetes crowd stomach situation in conjunction with the dietary fiber in carrot and the highland barley again, improve its quality of the life, prolong the complication disease time.
2, carrot nutritional is worth and enriches, and comprises multiple carrotene, electrolytes and minerals etc., therefore is known as " common people's ginseng ".Long-term edible carrot can reduce body inner cholesterol content, strengthen immunologic function and the wide intestines defaecation anti-cancer of sharp diaphragm.Employed carrot meal is the Ultramicro-powder through low temperature dewatering and superfine communication technique production among the present invention, this Ultramicro-powder has farthest kept the nutriment of carrot, and reached the granularity of breaking-wall cell, greatly increased the speed that nutritional labeling is dissolved in water.
3, the selected material of the present invention is plant or the plant extracts of integration of drinking and medicinal herbs, and safety non-toxic can eat for a long time, has no side effect.
4, selected beta glucan, carrot meal, highland barley flour and carrot meal and the alternative powder of highland barley flour of the present invention all has the hypoglycemic effect, and four have synergy, and effect is more obvious than single use beta glucan.
5, the present invention tests through reality, has effect hypoglycemic, reducing blood lipid.
⑴ experimenter selects
At 15 ~ 65 years old age, selection state of an illness after diet control or OHA treatment is more stable, does not need to change types of drugs and dosage, only takes the adult II diabetic of maintenance dose, fasting blood-glucose 〉=7.8mmol/L or postprandial blood sugar 〉=11.1mmol/L; Also can select the hyperglycemia population of 7.8mmol/L 〉=fasting blood-glucose 〉=6.7mmol/L or 11.1mmol/L 〉=fasting blood-glucose 〉=7.8mmol/L.
The experimenter can not be IDDM (insulin-dependent) patient; Age is at under-18s or over-65s, gestation or loner (referring in accordance with regulations diet control person); The complication such as the serious heart, liver, kidney are arranged through B ultrasonic, Chest X-rays and Electrocardioscopy, serious enterogastric diseases, or be associated with other serious primary disease persons, the mental patient; Diabetic ketosis, DKA and the infected were arranged in nearly 3 months; Take glucocorticoid and the frequent pharmacohistory person who uses other influences blood sugar; Take in a short time the article relevant with tested function, have influence on the judgement person to the result; Do not meet inclusive criteria, do not use in accordance with regulations given the test agent, can't fat fourth effect and data not umbra ring effect or security judgement person.
⑵ experimental design
The double blind random grouping is adopted in this experiment, between group and self two kinds of control design.According to above-mentioned Standard Selection trial volunteer, according to experimenter's blood sugar level, be divided at random test-meal group and control group, consider to affect as far as possible result's factor such as the course of disease, the kind of taking medicine (sulfonylureas and biguanides), sex, age etc.Carry out the harmony test, with the comparativity between the assurance group.
Before the experiment to each experimenter by sex, age, different labor intensity, ideal body weight, stipulate corresponding diet with reference to original habits and customs, each group of duration of test is adhered to diet control, and is former constant with medicament categories and dosage.The experimenter is by every day 3 times, and each 1 bag particle electuary (specification: took continuously 60 days by dosage 4.5 grams/bag).
The component of particles used electuary: beta glucan powder 58%, ultra micro highland barley flour 22%, ultra micro carrot meal 15%, antierythrite 5%, molecular clock monoglyceride 2.8 ‰, acesulfame potassium 1.5 ‰.After testing, the content of beta glucan is 23.2% in this prescription.
⑶ detect index
(when research finishes) experimenter detects fasting blood-glucose, the after the meal variation of 2 hours blood glucoses, glucose in urine and blood fat after the initial sum 60 days, also adds up the variation of experimenter's clinical symptoms simultaneously.
⑷ statistical procedures
Data result's poor expression of mean ± criterion numeral, self paired data adopts paired t-test, between test-meal group and the control group under the prerequisite of homogeneity of variance, mean relatively adopts in groups t check, otherwise adopt the t check after carrying out satisfying homogeneity of variance after variable transforms, if variance is appointed so uneven, adopt rank test.The efficient X that presses
2Check.
⑸ result
1. Symptom Observation: see Table 1,2, took tested material 60 days, before test-meal group clinical symptoms integration and self experiment and control group relatively, difference has conspicuousness (P＜0.05).Test-meal group clinical observation total effective rate is (72.55%), with control group (23.53%) comparing difference conspicuousness (P＜0.05) is arranged.
Table 1 clinical symptoms integration statistics (
± S)
Annotate: compare P＜0.05 before * and the test-meal; # and control group be P＜0.05 relatively.
Table 2 clinical symptoms are improved situation
Annotate: # and control group be P＜0.05 relatively.
2. fasting blood-glucose
See Table 3, test-meal group fasting blood-glucose and control group compare before the test-meal, no significant difference (P＞0.05).The front comparing difference of fasting blood-glucose and test-meal is without conspicuousness (P＞0.05) after the control group test-meal.Self relatively with after the test-meal compare before fasting blood-glucose and the test-meal after the test-meal of test-meal group, difference has conspicuousness (P＜0.05), test-meal group fasting blood-glucose fall is 1.84 ± 0.58 after the test-meal, compares (0.08 ± 0.56) with control group, and difference has conspicuousness (P＜0.05).Fasting blood-glucose descends 19.81% after the test-meal of test-meal group.
Fasting blood-glucose variation before and after table 3 test-meal (mmol/L,
± S)
Annotate: compare P＜0.05 before * and the test-meal; # and control group be P＜0.05 relatively.
3. postprandial blood sugar
See Table 4, test-meal group postprandial blood sugar and control group compare before the test-meal, no significant difference (P＞0.05).The front comparing difference of postprandial blood sugar and test-meal is without conspicuousness (P＞0.05) after the control group test-meal.Self relatively with after the test-meal compare before postprandial blood sugar and the test-meal after the test-meal of test-meal group, difference has conspicuousness (P＜0.05), test-meal group postprandial blood sugar fall is 1.87 ± 0.60 after the test-meal, compares (0.05 ± 0.82) with control group, and difference has conspicuousness (P＜0.05).Fasting blood-glucose descends 14.24% after the test-meal of test-meal group.
Postprandial blood sugar variation before and after table 4 test-meal (mmol/L,
± S)
Annotate: compare P＜0.05 before * and the test-meal; # and control group be P＜0.05 relatively.
4. glucose in urine
See Table 5, relatively all without obviously changing (P＞0.05), point out this composition that glucose in urine is had no significant effect between self more suddenly organizing before and after the glucose in urine test.
The variation of glucose in urine before and after table 5 test-meal (integrated value,
± S)
5. blood fat
Two groups of cholesterol (CHOL), triglycerides (TG), the horizontal situation of change of HDL (HDL-C) see Table 6, table 7, table 8.Before the test, control group and test-meal group change of serum C HOL, TG level compare, and no significant difference (P＞0.05) points out between two groups to have comparativity.Compare before CHOL, TG and the test-meal after the test-meal of test-meal group, difference has conspicuousness (P＜0.05), compares after CHOL, TG and the control group test after the test of test-meal group, and the HDL-C level has no obvious change (P＞0.05) before and after the test-meal.
Change of serum C HOL, TG, HDL-C level before and after table 6 test-meal
Change of serum C HOL, TG, HDL-C level before and after the table 7 test-meal test
Annotate: compare relatively P＜0.05 of P＜0.05 # and control group before * and the test-meal
Change of serum C HOL, the horizontal situation of change of TG, HDL-C before and after the table 8 test-meal test
6. security detects: body weight, blood pressure, heart rate, routine blood test, routine urinalysis (except the glucose in urine), stool routine examination, biochemical indicator and bad reaction observation etc.
Edible tested material 60 days, two groups of experimenter's body weight, blood pressure, heart rate, routine blood test, routine urinalysis (except the glucose in urine), stool routine examination, the every detection of biochemical indicator are all in normal range (NR).Do not find obvious adverse reaction during the test-meal.Illustrate tested material to body health without obvious damage.
7. conclusion
Adopt counter point between own control note group, select the trial volunteer who meets experimental condition to take tested material 60 days, during adhere to keeping on a diet, former treatment diabetes medicament and dosage are constant.The result shows: the composition of this invention is improved effect to the diabetes main clinic symptoms, and total effective rate is that the 72.55%(control group is 23.53%); Self relatively compares with control group before and after the test-meal of test-meal group fasting blood-glucose, difference all has conspicuousness (P＜0.05), test-meal group fasting blood-glucose fall and control group compare, and difference has conspicuousness (P＜0.05), and fasting blood-glucose test-meal group test-meal front and back are than descending 19.81% before the test-meal; Self relatively compares with control group before and after the test-meal of test-meal group postprandial blood sugar, difference all has conspicuousness (P＜0.05), test-meal group postprandial blood sugar fall and control group compare, and difference has conspicuousness (P＜0.05), and after the meal test-meal group of empty stomach test-meal front and back are than descending 14.24% before the test-meal.Illustrate that this composition has the effect of auxiliary hyperglycemic.
After the test-meal of test-meal group before CHOL, TG and the test-meal relatively, difference all has conspicuousness (P＜0.05), and descends more respectively 17.75%, 25.87% before CHOL, TG and the test-meal after the test-meal; Test-meal group CHOL, TG and control group compare after the test-meal, and difference all has conspicuousness (P＜0.05); Test-meal group HDL-C and control group comparing difference are without conspicuousness (P＞0.05) after the test-meal.Illustrate that this composition has the effect of auxiliary antilipemic.
The two groups of experimenter's body weight in test-meal front and back, blood pressure, heart rate, routine blood test, routine urinalysis (except the glucose in urine), stool routine examination, the every detection of biochemical indicator are all in normal range (NR).Do not find obvious adverse reaction during the test-meal.Illustrate tested material to body health without obvious damage.
The specific embodiment
Embodiment 1A kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 100%.
Wherein: the beta glucan powder is from the yeast of crossing 60 ~ 120 mesh sieves, and beta glucan mass content wherein 〉=20%.
Embodiment 2A kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 7.5%, ultra micro carrot meal 30%, ultra micro highland barley flour 30%, antierythrite 20%, isomalto-oligosaccharide 12.5%.
Wherein: the beta glucan powder is from the oat that crosses 60 ~ 120 mesh sieves, and beta glucan mass content wherein 〉=35%.
Embodiment 3A kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 20%, ultra micro carrot meal 20%, ultra micro highland barley flour 30%, antierythrite 10%, isomalto-oligosaccharide 20%.
Wherein: the beta glucan powder is from the barley that crosses 60 ~ 120 mesh sieves, and beta glucan mass content wherein 〉=40%.
Embodiment 4A kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 50%, ultra micro carrot meal 10%, ultra micro highland barley flour 20%, antierythrite 10%, isomalto-oligosaccharide 10%.
Wherein: the beta glucan powder is from the highland barley that crosses 60 ~ 120 mesh sieves, and beta glucan mass content wherein 〉=60%.
Above-mentioned
Embodiment 1 ~ 4In the ultra micro carrot meal with one or more replacements in the balsam pear of ultra micro, pumpkin, green tea, konjaku, hawthorn, ginkgo leaf, PORIA ALBA, lotus leaf, Chinese yam, the red date; One or more replacements in ultra micro highland barley flour corn, cocoa power, brown rice, the brewer's yeast.
Above-mentioned
Embodiment 1 ~ 4In beta-glucan composition food or the application in health food or the medicine hypoglycemic in preparation, that reduce cholesterol refer to contain this beta-glucan composition according to a conventional method granulation electuary, tablet, chewable tablets or capsule.
Claims (6)
1. beta-glucan composition, it is characterized in that: said composition is comprised of the raw material of following weight ratio: beta glucan powder 7.5 ~ 100%, ultra micro carrot meal 0 ~ 30%, ultra micro highland barley flour 0 ~ 30%, antierythrite 0 ~ 20%, isomalto-oligosaccharide 0 ~ 20%.
2. a kind of beta-glucan composition as claimed in claim 1 is characterized in that: a kind of from the yeast, oat, barley or the highland barley that cross 60 ~ 120 mesh sieves of described beta glucan powder, and beta glucan mass content wherein 〉=20%.
3. a kind of beta-glucan composition as claimed in claim 1 is characterized in that: a kind of from yeast, oat, barley or the highland barley of described beta glucan powder, and beta glucan mass content wherein 〉=35%.
4. a kind of beta-glucan composition as claimed in claim 1 is characterized in that: one or more replacements in the balsam pear of described ultra micro carrot meal usefulness ultra micro, pumpkin, green tea, konjaku, hawthorn, ginkgo leaf, PORIA ALBA, lotus leaf, Chinese yam, the red date.
5. a kind of beta-glucan composition as claimed in claim 1 is characterized in that: one or more replacements in described ultra micro highland barley flour corn, cocoa power, brown rice, the brewer's yeast.
6. a kind of beta-glucan composition as claimed in claim 1, food of reducing cholesterol hypoglycemic in preparation or the application in health food or the medicine is characterized in that: contain this beta-glucan composition according to a conventional method granulation electuary, tablet, chewable tablets or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210460788.5A CN102907606B (en) | 2012-11-16 | 2012-11-16 | Beta-glucan composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210460788.5A CN102907606B (en) | 2012-11-16 | 2012-11-16 | Beta-glucan composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102907606A true CN102907606A (en) | 2013-02-06 |
| CN102907606B CN102907606B (en) | 2014-04-16 |
Family
ID=47606369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210460788.5A Active CN102907606B (en) | 2012-11-16 | 2012-11-16 | Beta-glucan composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102907606B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405397A (en) * | 2013-08-30 | 2013-11-27 | 林宁 | Capsule located in bioadhesive drug delivery manner for releasing beta glucosan |
| CN104432037A (en) * | 2014-11-24 | 2015-03-25 | 广州市香雪制药股份有限公司 | Antioxidative health care nutrition composition, as well as preparation method and application thereof |
| CN107156851A (en) * | 2017-06-01 | 2017-09-15 | 四川惠泰农业科技有限公司 | Blood fat reducing health products containing beta glucan and preparation method thereof |
| CN107232610A (en) * | 2017-05-25 | 2017-10-10 | 杭州特悘衡康生物科技有限公司 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
| CN107950864A (en) * | 2017-11-21 | 2018-04-24 | 北京工商大学 | A kind of symphysis unit paddy vegetable meal replacement powder and its preparation method and application |
| CN112656768A (en) * | 2019-10-16 | 2021-04-16 | 天士力医药集团股份有限公司 | Traditional Chinese medicine concentrated pill and preparation method thereof |
| WO2023104181A1 (en) * | 2021-12-10 | 2023-06-15 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969674A (en) * | 2006-11-30 | 2007-05-30 | 吴江中怡实业有限公司 | Food additive |
| CN101816449A (en) * | 2010-05-07 | 2010-09-01 | 西藏天麦力健康品有限公司 | Highland barley composite nutrition stiff paste drink and preparation method thereof |
| CN101991786A (en) * | 2009-08-28 | 2011-03-30 | 江春艳 | Formula of medicine for reducing blood fat and preparations thereof |
-
2012
- 2012-11-16 CN CN201210460788.5A patent/CN102907606B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969674A (en) * | 2006-11-30 | 2007-05-30 | 吴江中怡实业有限公司 | Food additive |
| CN101991786A (en) * | 2009-08-28 | 2011-03-30 | 江春艳 | Formula of medicine for reducing blood fat and preparations thereof |
| CN101816449A (en) * | 2010-05-07 | 2010-09-01 | 西藏天麦力健康品有限公司 | Highland barley composite nutrition stiff paste drink and preparation method thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405397A (en) * | 2013-08-30 | 2013-11-27 | 林宁 | Capsule located in bioadhesive drug delivery manner for releasing beta glucosan |
| CN104432037A (en) * | 2014-11-24 | 2015-03-25 | 广州市香雪制药股份有限公司 | Antioxidative health care nutrition composition, as well as preparation method and application thereof |
| CN107232610A (en) * | 2017-05-25 | 2017-10-10 | 杭州特悘衡康生物科技有限公司 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
| CN107156851A (en) * | 2017-06-01 | 2017-09-15 | 四川惠泰农业科技有限公司 | Blood fat reducing health products containing beta glucan and preparation method thereof |
| CN107950864A (en) * | 2017-11-21 | 2018-04-24 | 北京工商大学 | A kind of symphysis unit paddy vegetable meal replacement powder and its preparation method and application |
| CN112656768A (en) * | 2019-10-16 | 2021-04-16 | 天士力医药集团股份有限公司 | Traditional Chinese medicine concentrated pill and preparation method thereof |
| WO2023104181A1 (en) * | 2021-12-10 | 2023-06-15 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102907606B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102907606B (en) | Beta-glucan composition and application thereof | |
| CN103099089B (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN105077236B (en) | Compound special meals nutrient powder of the highland barley of auxiliary hyperglycemic and preparation method thereof | |
| CN106983052A (en) | A kind of solid beverage of auxiliary hyperglycemic and preparation method thereof | |
| CN106666312A (en) | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof | |
| CN105211853A (en) | Blood sugar reducing health composition, electuary and preparation method thereof | |
| CN104146259B (en) | A kind of health-care flour for diabetic and preparation method thereof | |
| CN106692297A (en) | Composition for assistedly decreasing blood sugar, and preparation method and application thereof | |
| CN102293273A (en) | Health tea capable of adjusting blood pressure, blood sugar and blood fat and preventing thrombus and apoplexy | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN101756244A (en) | Functional food applicable to diabetic population | |
| CN101869283A (en) | Assistant hypoglycemia healthcare food of mulberry-leaf extract and preparation method thereof | |
| CN101878906A (en) | Health care food with auxiliary hyperglycemic function and preparation method thereof | |
| CN102613453B (en) | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application | |
| CN102422957A (en) | Bawei danshen tea and preparation process thereof | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN105795263A (en) | Health beverage for enhancing immunity and regulating human body functions and preparation method thereof | |
| CN102872423B (en) | Traditional Chinese medicine compound for treating glycuresis and preparation method thereof | |
| CN107568375A (en) | A kind of adlay slim tea and preparation method thereof | |
| CN104001072A (en) | Pharmaceutical composition for prevention and treatment of diabetes | |
| CN101804123A (en) | Plant raw material composition with anti-fatigue effect, preparation method, application and product thereof | |
| CN107260946A (en) | A kind of health-care edible capsule preparation method with auxiliary hyperglycemic function | |
| CN109157584B (en) | Composition with auxiliary blood fat reducing function and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 851400 No. 11, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region Patentee after: Tibet Qizheng Highland Barley Health Technology Co., Ltd. Address before: 850032 No. 189 Jinzhu West Road, Lhasa City, Tibet Autonomous Region Patentee before: Tibet Tianmaili Health Food Co., Ltd. |
|
| CP03 | Change of name, title or address |